US Stock MarketDetailed Quotes
DXCM DexCom
- 111.650
- -0.010-0.01%
Close Jul 22 16:00 ET
- 111.640
- -0.010-0.01%
Post 19:25 ET
44.40BMarket Cap72.50P/E (TTM)
113.250High110.750Low1.73MVolume112.760Open111.660Pre Close192.95MTurnover0.44%Turnover Ratio85.88P/E (Static)397.68MShares142.00052wk High19.76P/B43.97BFloat Cap74.75052wk Low--Dividend TTM393.86MShs Float164.863Historical High--Div YieldTTM2.24%Amplitude0.340Historical Low111.597Avg Price1Lot Size
DexCom Stock Forum
Sign in to post a comment
Stocks to Watch
Nike Inc (NKE US) $Nike(NKE.US$
Daily Chart -[BEARISH ↘ **]Nike shaped a bearish wedge breakdown. We prefer to stay bearish for now, expecting price to do a pause below 81.20 resistance before shaping a fresh drop towards 64.00 support. Technical indicators are advocating for a bearish scenario.
Alternatively: A daily candlestick close above 81.20 resistance will open a recovery towards the next resistance at 93.50.
Monde...
Nike Inc (NKE US) $Nike(NKE.US$
Daily Chart -[BEARISH ↘ **]Nike shaped a bearish wedge breakdown. We prefer to stay bearish for now, expecting price to do a pause below 81.20 resistance before shaping a fresh drop towards 64.00 support. Technical indicators are advocating for a bearish scenario.
Alternatively: A daily candlestick close above 81.20 resistance will open a recovery towards the next resistance at 93.50.
Monde...
+3
26
5
Nvidia delighted investors when it announced a 10-for-1 stock split last week. The move may be the start of a trend, as several prominent tech companies trade at prices high enough to tip the scales toward similar splits, according to a note from Bank of America.
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
The bank highlights 36 S&P 500 companies with stock prices above $500, a level suggesting they may be candidates for splits. $Broadcom(AVGO.US$, $Super Micro Computer(SMCI.US$ , ...
75
2
$Microsoft(MSFT.US$ - They make money and do AI things so it will drop -20%
- Bull Case - They lose a lot of money
- Bear Case - They make a lot of money and they're involved in AI
$Alphabet-A(GOOGL.US$ (forgot) - They make money and AI so it will drop -18.75%
- Bull Case - They lose money and search market share shrinks heavily. They have Googler's streak through Pinchia's office for a group sit-in regarding go...
- Bull Case - They lose a lot of money
- Bear Case - They make a lot of money and they're involved in AI
$Alphabet-A(GOOGL.US$ (forgot) - They make money and AI so it will drop -18.75%
- Bull Case - They lose money and search market share shrinks heavily. They have Googler's streak through Pinchia's office for a group sit-in regarding go...
16
5
After-hours Stock Action
CrowdStrike ( $CrowdStrike(CRWD.US$ ): Cybersecurity Juggernaut
- Post-Earnings Surge: Up over 20% after beating estimates and strong guidance.
- Stellar Performance: Stock up over 130% in the past year, outperforming First Trust Cybersecurity ETF ( $First Trust Exch Traded Fund 2 Nasdaq Cybersecurity Etf(CIBR.US$ ).
Paccar ( $PACCAR Inc(PCAR.US$ ): Record High on Price Target Hike
JPMorgan Boost: Reiterated overwei...
CrowdStrike ( $CrowdStrike(CRWD.US$ ): Cybersecurity Juggernaut
- Post-Earnings Surge: Up over 20% after beating estimates and strong guidance.
- Stellar Performance: Stock up over 130% in the past year, outperforming First Trust Cybersecurity ETF ( $First Trust Exch Traded Fund 2 Nasdaq Cybersecurity Etf(CIBR.US$ ).
Paccar ( $PACCAR Inc(PCAR.US$ ): Record High on Price Target Hike
JPMorgan Boost: Reiterated overwei...
DexCom's start of profitability could signal fast earnings growth, justifying strong share price gains. Despite recent slowdown, the company might continue to execute with prowess.
DexCom's recent profitability and reinvestment are positive signs. The stock's 225% return over five years indicates investors recognize these changes. If maintained, DexCom could have a promising future.
DexCom's high P/S ratio is justified by its superior revenue growth and future prospects. Investors' confidence in the company's future revenues is reflected in this ratio, suggesting the share price won't fall significantly soon.
Despite DexCom's higher-than-average return on equity, the company's high debt levels could pose a significant risk. While debt can boost return on equity, it is only justifiable when a company can generate substantial returns from it.
Baird analysts anticipate Insulet's earnings to grow faster than their annual sales of approx. 20%. DexCom's margins predicted to expand with sales growth over 20% annually before GLP-1s impact. Boston Scientific considered a top-level medtech enterprise by Baird's Rescott.
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Cui Nyonya Kueh : uncle @soyabean89 ... fyi .
soyabean89 Cui Nyonya Kueh: Nike still got room to drop?!
brutal
Trader’s EdgeOP soyabean89: The bearish momentum on the Weekly chart and the Daily chart does look very strong.. - Isaac
12moon : It is interesting to hear from Trader's Edge,but it is risky to follow blindly. Weekly view is too speculative
Cui Nyonya Kueh : "This report is provided for informational and general circulation purposes only and should not be construed as an offer, solicitation, or recommendation for the purchase or sale of securities, futures, or other investment products. It does not take into consideration any particular needs of any person. This advertisement has not been reviewed by the Monetary Authority of Singapore."